Leukemia is a broad term covering a spectrum of diseases characterised by the formation of abnormal blood cells. Clinically, leukemia are divided into two sub-categories: acute, with the apparition of a large number of immature blood cells; or chronic, with the build-up of relatively mature but still abnormal blood cells. The acute form requires immediate treatment and is the most common form of leukaemia in children. By opposition, the chronic disease is less aggressive and can be monitored to establish the appropriate treatment. This form of leukemia is generally found in older patients. In addition, leukemia can be either from lymphoid or myeloid origin depending on the type of carcinogenic progenitor. A number of treatments have successfully been identified to treat leukemia, however, resistance issues as well as fundamental problems around the formation of the disease remain unsolved and need to be addressed to propose new treatment avenues.
BRIO program focuses on chronic myeloid leukemia (CML). Around Prof. F.X. Mahon (INSERM/Bordeaux University) a number of research centres work on this project:
- Unit INSERM 1035 (team Leukemic Haematopoiesis and Therapeutic Targets Laboratory)
- Bergonié Institute
- Bordeaux University
- Institut Polytechnique de Bordeaux
- Bordeaux Hospital (CHU de Bordeaux)
BRIO work will focus on three axes :
- Understand the mechanisms of leukemogenesis of CML and other myeloid disorders to identify potential new therapeutic targets;
- Establish the mechanisms of tyrosine kinase inhibition and resistance in CML, and characterise alternative treatment choice;
- Translational and clinical research of CML and AML (acute myeloid leukemia) to select the appropriate treatment.